LIXTE Biotechnology Advances First-in-Class Approach to Enhance Cancer Therapies

LIXTE Biotechnology Holdings, a clinical-stage pharmaceutical company, is pursuing a first-in-class approach to enhance established cancer therapies by targeting a fundamental biological pathway involved in tumor survival and resistance. The company’s strategy focuses on protein phosphatase 2A, an enzyme that regulates cell growth, DNA repair, and survival signaling. In many cancers, PP2A activity enables tumor cells to recover from treatment damage, contributing to resistance and disease progression.

The company’s proprietary compound, LB-100, is a small-molecule PP2A inhibitor designed to temporarily disrupt these repair mechanisms when cancer cells are exposed to therapy. Preclinical research shows this disruption can make tumor cells more vulnerable to chemotherapy and immunotherapy, increasing treatment effectiveness without introducing a new cytotoxic agent. LIXTE has demonstrated that LB-100 is well-tolerated in cancer patients at doses associated with anti-cancer activity.

Based on extensive published preclinical data available at https://www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. The compound is part of a pioneering effort in an entirely new field of cancer biology called activation lethality, which represents a new treatment paradigm. LIXTE’s approach is covered by a comprehensive patent portfolio, and proof-of-concept clinical trials are currently in progress for ovarian clear cell carcinoma and metastatic colon cancer.

The company’s strategy represents a significant shift from developing standalone treatments to enhancing existing therapies. By targeting PP2A, LIXTE aims to address a common mechanism of treatment resistance that affects multiple cancer types. This approach could potentially make current treatments more effective without requiring patients to switch to entirely new therapeutic regimens. The clinical-stage development of LB-100 marks an important step in testing whether targeting cellular repair mechanisms can overcome one of the most challenging aspects of cancer treatment: the development of resistance to therapy.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is LIXTE Biotechnology Advances First-in-Class Approach to Enhance Cancer Therapies.

The post LIXTE Biotechnology Advances First-in-Class Approach to Enhance Cancer Therapies appeared first on citybuzz.